CD8A and neoplasm: In summary, the current study demonstrated that IL-36β could promote CD8+ T cell activation and antitumor immune responses by activating mTORC1 through PI3K/Akt, IKK, and MyD88 pathways, and proved that IL-36β had potential application value in tumor immunotherapy.